7Baggers

AbCellera Biologics Inc
(NASDAQ:ABCL) 

ABCL stock logo

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are e...

Founded: 2012
Full Time Employees: 174
CEO: Carl Hansen  
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 
                        
      revenue:
    		                    
      research fees
    		8,817,000 6,639,000 4,068,000 4,768,000 6,289,000 5,453,000 9,774,000 8,744,000 6,413,000 9,830,000 10,570,000 11,424,000 7,508,000 12,538,000 9,333,000 4,746,000 5,128,000 5,215,000 3,986,000  
      licensing revenue
    		138,000 10,445,000 167,000 282,000 218,000 370,000 180,000 185,000 186,000 226,000 372,000 165,000 154,000 147,000 231,000 86,000 190,000 263,000 20,259,000  
      milestone payments
    		     1,500,000  250,000   1,250,000 500,000 400,000     1,000,000 7,000,000  
      total revenue
    		8,955,000 17,084,000 4,235,000 5,050,000 6,507,000 7,323,000 9,954,000 9,179,000 6,599,000 10,056,000 12,192,000 21,545,000 101,383,000 45,917,000 316,581,000 139,331,000 5,508,000 27,643,000 202,741,000  
      yoy
    		37.62% 133.29% -57.45% -44.98% -1.39% -27.18% -18.36% -57.40% -93.49% -78.10% -96.15% -84.54% 1740.65% 66.11% 56.15%      
      qoq
    		-47.58% 303.40% -16.14% -22.39% -11.14% -26.43% 8.44% 39.10% -34.38% -17.52% -43.41% -78.75% 120.80% -85.50% 127.22% 2429.61% -80.07% -86.37%   
      operating expenses:
    		                    
      research and development
    		55,028,000 39,213,000 42,496,000 46,076,000 40,969,000 40,927,000 39,287,000 48,622,000 37,917,000 36,473,000 52,647,000 28,245,000 26,582,000 26,685,000 26,366,000 17,209,000 17,450,000 15,046,000 12,352,000  
      sales and marketing
    		2,906,000 3,009,000 2,842,000 3,144,000 3,135,000 3,136,000 3,365,000 3,100,000 3,468,000 3,841,000 3,771,000 2,691,000 3,089,000 3,120,000 2,370,000 1,827,000 1,217,000 1,295,000 2,578,000  
      general and administrative
    		22,052,000 18,977,000 16,226,000 16,020,000 19,147,000 20,192,000 17,352,000 15,974,000 14,369,000 15,521,000 15,134,000 13,015,000 13,792,000 14,412,000 14,268,000 12,890,000 11,271,000 11,203,000 6,422,000  
      depreciation, amortization, and impairment
    		5,247,000 5,470,000  12,565,000 36,919,000 36,522,000               
      total operating expenses
    		85,233,000 66,669,000 66,895,000 77,805,000 100,170,000 100,777,000 64,848,000 75,232,000 61,489,000 61,445,000 77,066,000 59,323,000 63,648,000 54,313,000 91,631,000 57,778,000 33,604,000 34,676,000 44,667,000  
      income from operations
    		-76,278,000 -49,585,000 -62,660,000 -72,755,000 -93,663,000 -93,454,000 -54,894,000 -66,053,000 -54,890,000 -51,389,000 -64,874,000 -37,778,000 37,735,000 -8,396,000 224,950,000 81,553,000 -28,096,000 -7,033,000 158,074,000  
      yoy
    		-18.56% -46.94% 14.15% 10.15% 70.64% 81.86% -15.38% 74.85% -245.46% 512.07% -128.84% -146.32% -234.31% 19.38% 42.31%      
      qoq
    		53.83% -20.87% -13.88% -22.32% 0.22% 70.24% -16.89% 20.34% 6.81% -20.79% 71.72% -200.11% -549.44% -103.73% 175.83% -390.27% 299.49% -104.45%   
      operating margin %
    		-851.79% -290.24% -1479.57% -1440.69% -1439.42% -1276.17% -551.48% -719.61% -831.79% -511.03% -532.10% -175.34% 37.22% -18.29% 71.06% 58.53% -510.09% -25.44% 77.97%  
      other income:
    		                    
      interest income
    		-6,765,000 -7,592,000 -8,051,000 -8,668,000 -9,603,000 -9,801,000 -10,401,000              
      grants and incentives
    		-2,729,000 -3,692,000 -4,153,000 -3,544,000 -3,491,000 -3,310,000 -3,275,000 -3,376,000 -2,828,000 -4,576,000 -3,374,000 -1,675,000 -2,150,000 -1,535,000 -5,194,000 -5,312,000 -4,380,000 -4,646,000 -3,148,000  
      other
    		1,984,000 -1,957,000 2,528,000    1,529,000 -3,106,000 -2,046,000 1,970,000 -3,593,000          
      total other income
    		-7,510,000 -13,241,000 -9,676,000 -25,926,000 -31,031,000             -4,960,000 -3,413,000  
      net income before income tax
    		-68,768,000 -36,344,000  -38,391,500 -62,632,000 -48,187,000 -42,747,000              
      income tax recovery
    		-11,649,000 -1,617,000 -7,363,000 -6,229,750 -11,525,000 -11,257,000 -2,137,000              
      net income
    		-57,119,000 -34,727,000 -45,621,000 -32,161,750 -51,107,000 -36,930,000 -40,610,000              
      yoy
    		11.76% -5.97% 12.34%                  
      qoq
    		64.48% -23.88% 41.85% -37.07% 38.39% -9.06%               
      net income margin %
    		-637.84% -203.27% -1077.24% -636.87% -785.42% -504.30% -407.98% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%  
      foreign currency translation adjustment
    		-41,000 4,341,000 -2,620,000 -3,146,000 841,000 -257,000 -96,000 -260,000 439,000 122,000 -630,000 -674,000 -1,293,000 -211,000 507,000 -364,000 -1,508,000 2,152,000   
      comprehensive loss
    		-57,160,000 -30,386,000 -48,241,000 -32,039,750 -50,266,000 -37,187,000 -40,706,000              
      net income per share
    		                    
      basic
    		-0.19 -0.12 -0.15 -0.11 -0.17 -0.13 -0.14              
      diluted
    		-0.19 -0.12 -0.15 -0.11 -0.17 -0.13 -0.14              
      weighted-average common shares outstanding
    		                    
      basic
    		298,875,174 298,508,601 297,692,663 294,327,532 294,851,945 294,217,013 292,723,901 289,166,486 289,496,841 288,905,587 287,767,136 285,056,606 285,322,719 284,686,542 283,895,020 275,763,745 278,933,760 272,196,107 269,697,212  
      diluted
    		298,875,174 298,508,601 297,692,663 294,327,532 294,851,945 294,217,013 292,723,901 289,166,486 289,496,841 288,905,587 287,767,136 314,827,255 315,818,163 284,686,542 311,482,017 318,294,236 278,933,760 272,196,107 320,282,747  
      depreciation and amortization
    		  5,331,000    4,844,000 4,214,750 5,735,000 5,610,000 5,514,000 3,506,250 5,150,000 4,886,000 3,990,000 3,958,000 3,666,000 3,522,000 3,305,000  
      other expense:
    		                    
      net loss before income tax
    		  -52,984,000                  
      balances as of december 31, 2024
    		  777,171                  
      shares issued and restricted stock units ("rsus") vested under stock option plan
    		  12,897                  
      stock-based compensation
    		                    
      balances as of march 31, 2025
    		  790,068                  
      other income
    		   -12,141,000 -17,937,000 -32,156,000         -665,000      
      total other
    		     -45,267,000 -12,147,000 -17,451,000 -15,614,000 -13,385,000 -16,726,000 -4,055,500 -8,852,000 -1,510,000 -5,859,000      
      royalty revenue
    		           9,456,000 93,321,000 33,232,000 307,017,000 134,499,000 190,000 21,165,000 171,496,000  
      royalty fees
    		           1,554,000 15,035,000 5,210,000 44,637,000 21,894,000  3,610,000 20,010,000  
      other expense
    		           -1,835,750 -6,702,000 25,000  148,750 1,256,000 -314,000 -265,000  
      interest
    		       -10,969,000 -10,740,000 -10,779,000 -9,759,000          
      net earnings before income tax
    		       -48,602,000 -39,276,000 -38,004,000 -48,148,000 -31,412,000 46,587,000 -6,886,000 230,809,000 84,710,000 -24,972,000 -2,073,000 161,487,000  
      income tax (recovery) expense
    		       -1,452,000 -10,666,000 -7,476,000 -8,038,000 20,524,750 19,963,000 -101,000       
      net earnings
    		       -47,150,000 -28,610,000 -30,528,000 -40,110,000 -29,893,000 26,624,000 -6,785,000 168,573,000 59,948,000 -21,380,000 -2,323,000   
      comprehensive income
    		       -47,410,000 -28,171,000 -30,406,000 -40,740,000 -30,567,000 25,331,000 -6,996,000 169,080,000 59,584,000 -22,888,000 -171,000   
      net earnings per share attributable to common shareholders
    		                    
      basic
    		       -0.17 -0.1 -0.11 -0.14 -0.1 0.09 -0.02 0.59 0.22 -0.08 -0.01 0.43  
      diluted
    		       -0.17 -0.1 -0.11 -0.14 -0.1 0.08 -0.02 0.54 0.19 -0.08 -0.01 0.37  
      income tax expense
    		              62,236,000      
      total other expense
    		               -2,894,750 -3,124,000    
      income tax
    		               10,230,750 -3,592,000    
      provision for income tax
    		                 250,000 44,266,000  
      net earnings and comprehensive income for the period
    		                  117,221,000  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 
                            
        assets
      		                      
        current assets:
      		                      
        cash and cash equivalents
      		77,063,000 128,513,000 83,159,000 92,437,000 159,266,000 156,325,000 126,640,000 148,312,000 123,572,000 133,320,000 172,422,000 179,747,000 193,017,000 386,535,000 371,973,000 790,615,000 545,718,000 476,142,000 517,694,000 792,571,000 685,795,000 594,116,000 
        marketable securities
      		427,669,000 405,313,000 412,513,000 460,641,000 446,000,000 469,289,000 516,499,000 522,044,000 574,451,000 627,265,000 613,418,000 615,947,000 603,478,000 499,950,000 496,233,000 231,652,000 240,335,000 246,835,000 235,785,000    
        total cash, cash equivalents, and marketable securities
      		504,732,000 533,826,000 495,672,000 553,078,000 605,266,000 625,614,000 643,139,000 670,356,000 698,023,000 760,585,000 785,840,000 795,694,000 796,495,000 886,485,000 868,206,000 1,022,267,000 786,053,000 722,977,000 753,479,000    
        accounts and accrued receivable
      		36,761,000 58,293,000 41,456,000 47,310,000 40,005,000 33,616,000 31,373,000 36,143,000 34,419,000 30,590,000 37,446,000 45,678,000 20,003,000 38,593,000 105,964,000 52,797,000 334,403,000 160,576,000 43,633,000    
        restricted cash
      		25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000 25,000,000     
        other current assets
      		98,103,000 111,113,000 133,012,000 116,757,000 94,707,000 67,140,000 43,371,000 40,055,000 56,506,000 55,810,000 71,232,000 64,363,000 99,155,000 75,413,000 46,499,000 43,891,000 28,922,000 21,247,000 6,635,000 6,547,000 5,745,000 5,970,000 
        total current assets
      		664,596,000 728,232,000 695,140,000 742,145,000 764,978,000 751,370,000 742,883,000 771,554,000 813,948,000 871,985,000 919,518,000 930,735,000 940,653,000 1,025,491,000 1,045,669,000 1,143,955,000 1,174,378,000 929,800,000 803,747,000 864,002,000 907,982,000 813,325,000 
        long-term assets:
      		                      
        property and equipment
      		422,806,000 428,003,000 427,358,000 424,020,000 347,102,000 340,429,000 331,263,000 318,882,000 306,081,000 287,696,000 277,209,000 259,640,000 233,187,000 217,255,000 200,602,000 149,178,000 122,049,000 111,616,000 91,584,000 87,479,000 34,618,000 17,923,000 
        intangible assets
      		37,460,000 38,381,000 39,321,000 40,262,000 41,192,000 42,113,000 52,577,000 85,661,000 118,736,000 120,425,000 124,076,000 126,747,000 128,845,000 131,502,000 142,548,000 143,179,000 145,785,000 148,392,000 148,821,000 110,223,000 112,688,000 115,153,000 
        goodwill
      		47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 47,806,000 49,457,000 31,500,000 31,500,000 31,500,000 
        investments in equity accounted investees
      		65,308,000 62,580,000 93,301,000 90,374,000 81,567,000 82,297,000 84,084,000 76,064,000 71,592,000              
        other long-term assets
      		69,136,000 51,948,000 53,066,000 57,454,000 61,563,000 96,538,000 134,215,000 112,514,000 104,933,000 94,244,000 80,694,000 113,446,000 89,845,000 46,331,000 49,066,000 43,842,000 43,389,000 30,642,000 31,616,000 15,947,000 9,548,000 8,388,000 
        total long-term assets
      		642,516,000 628,718,000 660,852,000 659,916,000 579,230,000 609,183,000 649,945,000 640,927,000 649,148,000 616,109,000 592,672,000 606,431,000 557,266,000 515,416,000 506,740,000 449,829,000 417,911,000 388,769,000 368,985,000 287,854,000 220,541,000 192,211,000 
        total assets
      		1,307,112,000 1,356,950,000 1,355,992,000 1,402,061,000 1,344,208,000 1,360,553,000 1,392,828,000 1,412,481,000 1,463,096,000 1,488,094,000 1,512,190,000 1,537,166,000 1,497,919,000 1,540,907,000 1,552,409,000 1,593,784,000 1,592,289,000 1,318,569,000 1,172,732,000 1,151,856,000 1,128,523,000 1,005,536,000 
        liabilities and shareholders' equity
      		                      
        current liabilities:
      		                      
        accounts payable and other current liabilities
      		39,551,000 50,781,000 53,117,000 50,074,000 47,840,000 55,004,000 53,773,000 43,952,000 42,887,000              
        deferred revenue
      		7,743,000 13,526,000 15,687,000 16,949,000 18,785,000 13,521,000 5,578,000 6,401,000 10,565,000 18,958,000 17,508,000 8,542,000 11,807,000 21,612,000 6,815,000 4,621,000 9,190,000 7,536,000 6,170,000 10,568,000 11,306,000 6,589,000 
        total current liabilities
      		47,294,000 64,307,000 68,804,000 67,023,000 75,396,000 76,612,000 79,568,000 70,380,000 104,883,000 119,013,000 110,239,000 118,905,000 89,591,000 118,320,000 106,052,000 221,140,000 213,418,000 120,676,000 49,549,000 69,758,000 88,395,000 103,490,000 
        long-term liabilities:
      		                      
        operating lease liability
      		134,309,000 137,403,000 137,052,000 137,184,000 63,210,000 60,743,000 66,274,000 66,451,000 68,079,000 71,222,000 75,185,000 78,079,000 77,265,000 76,675,000 71,591,000 32,759,000 36,356,000 36,413,000 27,264,000 31,020,000 16,973,000 3,715,000 
        deferred government contributions
      		176,105,000 174,453,000 169,118,000 167,532,000 157,193,000 149,893,000 142,046,000 124,186,000 110,579,000 95,915,000 84,072,000 76,354,000           
        other long-term liabilities
      		11,321,000 4,768,000 1,386,000 1,560,000 1,624,000 1,469,000 1,524,000 6,348,000 5,735,000 5,906,000 5,051,000 2,333,000 2,962,000 3,086,000 2,857,000 2,984,000 3,430,000 1,733,000 1,695,000 1,657,000 931,000 4,422,000 
        total long-term liabilities
      		321,735,000 325,739,000 323,150,000 327,962,000 245,830,000 227,857,000 235,166,000 231,133,000 228,300,000 216,763,000 219,176,000 223,434,000 199,828,000 189,310,000 196,185,000 159,788,000 171,364,000 172,160,000 169,786,000 114,419,000 83,004,000 71,538,000 
        total liabilities
      		369,029,000 390,046,000 391,954,000 394,985,000 321,226,000 304,469,000 314,734,000 301,513,000 333,183,000 335,776,000 329,415,000 342,339,000 289,419,000 307,630,000 302,237,000 380,928,000 384,782,000 292,836,000 219,335,000 184,177,000 171,399,000 175,028,000 
        commitments and contingencies
      		                      
        shareholders' equity:
      		                      
        common shares: no par value, unlimited authorized shares at december 31, 2025 and march 31, 2026: 300,600,710 and 303,945,581 shares issued and outstanding at december 31, 2025 and march 31, 2026, respectively
      		816,533,000                      
        additional paid-in capital
      		196,616,000 198,279,000 192,804,000 181,483,000 168,603,000 166,361,000 155,354,000 140,828,000 127,990,000 121,052,000 109,384,000 96,423,000 81,630,000 74,118,000 64,384,000 56,001,000 44,726,000 35,357,000 26,945,000 21,669,000 14,562,000 5,919,000 
        accumulated other comprehensive loss
      		-2,419,000 -4,234,000 -2,698,000 -2,657,000 -6,998,000 -4,378,000 -1,232,000 -2,073,000 -1,816,000              
        accumulated deficit
      		-72,647,000                      
        total shareholders' equity
      		938,083,000 966,904,000 964,038,000 1,007,076,000 1,022,982,000 1,056,084,000 1,078,094,000 1,110,968,000 1,129,913,000 1,152,318,000 1,182,775,000 1,194,827,000 1,208,500,000 1,233,277,000 1,250,172,000 1,212,856,000 1,207,507,000 1,025,733,000 953,397,000 967,679,000 957,124,000 830,508,000 
        total liabilities and shareholders' equity
      		1,307,112,000 1,356,950,000 1,355,992,000 1,402,061,000 1,344,208,000 1,360,553,000 1,392,828,000 1,412,481,000 1,463,096,000 1,488,094,000 1,512,190,000 1,537,166,000 1,497,919,000 1,540,907,000 1,552,409,000 1,593,784,000 1,592,289,000 1,318,569,000 1,172,732,000 1,151,856,000 1,128,523,000 1,005,536,000 
        contingent consideration payable
      		    8,771,000 8,087,000 20,217,000 20,027,000 51,431,000 50,475,000 53,929,000 54,874,000 15,733,000 16,054,000 25,392,000 24,629,000 30,623,000 35,886,000 44,948,000 9,614,000 9,378,000 9,148,000 
        deferred tax liability
      		 9,115,000 9,744,000 10,053,000 10,053,000 10,052,000 12,781,000 21,737,000 30,274,000 30,612,000 33,178,000 33,178,000 33,426,000 33,178,000 34,143,000 34,616,000 36,804,000 37,370,000 36,197,000 25,510,000 26,992,000 26,161,000 
        common shares: no par value, unlimited authorized shares at december 31, 2024 and december 31, 2025: 295,757,002 and 300,600,710 shares issued and outstanding at december 31, 2024 and december 31, 2025, respectively
      		 802,341,000                     
        accumulated earnings
      		 -29,482,000 -20,537,000 36,582,000 71,309,000 116,930,000 151,140,000 202,247,000 239,177,000 279,787,000 326,937,000 355,547,000 386,075,000 426,185,000 456,078,000 429,454,000 436,239,000 267,666,000 207,720,000 229,100,000 231,423,000 114,202,000 
        common shares: no par value, unlimited authorized shares at december 31, 2024 and september 30, 2025: 295,757,002 and 299,011,566 shares issued and outstanding at december 31, 2024 and september 30, 2025, respectively
      		  794,469,000                    
        common shares: no par value, unlimited authorized shares at december 31, 2024 and june 30, 2025: 295,757,002 and 298,652,967 shares issued and outstanding at december 31, 2024 and june 30, 2025, respectively
      		   791,668,000                   
        common shares: no par value, unlimited authorized shares at december 31, 2024 and march 31, 2025: 295,757,002 and 298,355,752 shares issued and outstanding at december 31, 2024 and march 31, 2025, respectively
      		    790,068,000                  
        common shares: no par value, unlimited authorized shares at december 31, 2023 and december 31, 2024: 290,824,970 and 295,757,002 shares issued and outstanding at december 31, 2023 and december 31, 2024, respectively
      		     777,171,000                 
        common shares: no par value, unlimited authorized shares at december 31, 2023 and september 30, 2024: 290,824,970 and 295,157,474 shares issued and outstanding at december 31, 2023 and september 30, 2024, respectively
      		      772,832,000                
        common shares: no par value, unlimited authorized shares at december 31, 2023 and june 30, 2024: 290,824,970 and 294,665,532 shares issued and outstanding at december 31, 2023 and june 30, 2024, respectively
      		       769,966,000               
        common shares: no par value, unlimited authorized shares at december 31, 2023 and march 31, 2024: 290,824,970 and 293,621,312 shares issued and outstanding at december 31, 2023 and march 31, 2024, respectively
      		        764,562,000              
        investments in and loans to equity accounted investees
      		         65,938,000 62,887,000 58,792,000 57,583,000 72,522,000 66,718,000 65,824,000 58,882,000 50,313,000 47,507,000 42,705,000 32,187,000  
        accounts payable and other liabilities
      		         49,580,000 35,708,000 52,395,000 31,814,000 33,150,000 25,866,000 24,390,000 25,717,000 32,017,000 24,072,000 18,276,000 13,287,000  
        common shares: no par value, unlimited authorized shares at december 31, 2022 and december 31, 2023: 286,851,595 and 290,824,970 shares issued and outstanding at december 31, 2022 and december 31, 2023, respectively
      		         753,199,000             
        accumulated other comprehensive income
      		         -1,720,000    -1,391,000 -717,000 576,000 787,000 280,000 644,000 2,152,000   
        accrued royalties payable
      		          3,094,000 3,094,000 3,094,000 19,347,000 17,822,000 50,555,000 45,364,000 22,506,000 595,000 23,520,000 20,010,000 27,143,000 
        common shares: no par value, unlimited authorized shares at december 31, 2022 and september 30, 2023: 286,851,595 and 289,777,654 shares issued and outstanding at december 31, 2022 and september 30, 2023, respectively
      		          747,914,000            
        accumulated other comprehensive
      		          -1,460,000 -1,899,000 -2,021,000          
        common shares: no par value, unlimited authorized shares at december 31, 2022 and june 30, 2023: 286,851,595 and 289,189,469 shares issued and outstanding at december 31, 2022 and june 30, 2023, respectively
      		           744,756,000           
        current portion of contingent consideration payable
      		            42,876,000 44,211,000 32,531,000 34,252,000 27,499,000 22,934,000 12,122,000 11,572,000 13,762,000 13,411,000 
        deferred grant funding
      		            45,026,000 40,801,000         
        common shares: no par value, unlimited authorized shares at december 31, 2022 and march 31, 2023: 286,851,595 and 288,426,514 shares issued and outstanding at december 31, 2022 and march 31, 2023, respectively
      		            742,816,000          
        income taxes payable
      		              23,018,000 107,322,000 105,648,000 35,683,000 6,590,000 5,822,000 30,030,000 36,152,000 
        common shares: no par value, unlimited authorized shares at december 31, 2021 and 2022: 283,257,104 and 286,851,595 shares issued and outstanding at december 31, 2021 and 2022 respectively
      		             734,365,000         
        subsequent event
      		                      
        deferred revenue and grant funding
      		              62,202,000 64,800,000 64,151,000 60,758,000 59,682,000 46,618,000 28,730,000 25,894,000 
        common shares: no par value, unlimited authorized shares at december 31, 2021 and september 30, 2022: 283,257,104 and 285,761,492 shares issued and outstanding at december 31, 2021 and september 30, 2022, respectively
      		              730,427,000        
        common shares: no par value, unlimited authorized shares at december 31, 2021 and june 30, 2022: 283,257,104 and 285,052,302 shares issued and outstanding at december 31, 2021 and june 30, 2022, respectively
      		               726,825,000       
        subsequent events
      		                      
        common shares: no par value, unlimited authorized shares at december 31, 2021 and march 31, 2022: 283,257,104 and 284,521,181 shares issued and outstanding at december 31, 2021 and march 31, 2022, respectively
      		                725,755,000      
        common shares: no par value, unlimited authorized shares at december 31, 2020 and 2021: 269,497,768 and 283,257,104 shares issued and outstanding at december 31, 2020 and 2021 respectively
      		                 722,430,000     
        long term assets:
      		                      
        common shares: no par value, unlimited authorized shares at december 31, 2020 and september 30, 2021: 269,497,768 and 281,151,877 shares issued and outstanding at december 31, 2020 and september 30, 2021 respectively
      		                  718,088,000    
        accounts receivable
      		                   2,799,000 23,371,000 903,000 
        accrued accounts receivable
      		                   62,085,000 193,071,000 212,336,000 
        common shares: no par value, unlimited authorized shares at december 31, 2020 and june 30, 2021: 269,497,768 and 276,982,678 shares issued and outstanding at december 31, 2020 and june 30, 2021 respectively
      		                   714,758,000   
        common shares: no par value, unlimited authorized shares at december 31, 2020 and march 31, 2021: 269,497,768 and 270,925,930 shares issued and outstanding at december 31, 2020 and march 31, 2021 respectively
      		                    711,139,000  
        equity investee
      		                     19,247,000 
        loans to related parties
      		                      
        accounts payable and accrued liabilities
      		                     20,005,000 
        current portion of long-term debt
      		                     190,000 
        long-term debt
      		                     2,198,000 
        common shares: no par value, unlimited authorized shares at december 31, 2019 and 2020: 151,681,382 and 269,497,768 shares issued and outstanding at december 31, 2019 and 2020 respectively
      		                     710,387,000 
        convertible preferred shares unlimited authorized shares at december 31, 2019 and 2020: 2,105,264 and nil issued and outstanding at december 31, 2019 and 2020 respectively
      		                      
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 
                             
          cash flows from operating activities:
        		                     
          net loss
        		-43,165,000 -8,945,000 -57,119,000 -34,727,000 -45,621,000  -51,107,000 -36,930,000 -40,610,000             
          depreciation of property and equipment
        		5,918,000 5,182,000 4,306,000 4,542,000 4,409,000 2,100,000 3,834,000 3,448,000 3,155,000 3,884,000 3,064,000 2,952,000 2,858,000 2,741,000 2,531,000 2,290,000 1,391,000 1,343,000 1,163,000 1,057,000 840,000 
          amortization of intangible assets
        		920,000    922,000    1,689,000  2,671,000 2,658,000 2,656,000  2,631,000 2,607,000 2,606,000 2,630,000 2,502,000 2,465,000 2,465,000 
          amortization of operating lease right-of-use assets
        		1,817,000 1,797,000 1,990,000 1,589,000 1,274,000 1,336,000 1,376,000 1,515,000 1,922,000 1,573,000 1,674,000 1,646,000 1,606,000 1,573,000 1,566,000 1,144,000 976,000 890,000    
          stock-based compensation
        		12,013,000 12,904,000 13,895,000 14,207,000 14,786,000 15,226,000 17,164,000 17,782,000 17,409,000 16,448,000 15,862,000 16,399,000 15,474,000 13,323,000 11,754,000 12,113,000 12,291,000 9,038,000 7,708,000 8,473,000 5,427,000 
          other
        		2,377,000 -4,319,000 1,655,000     -9,900,000 1,707,000 6,631,000 -1,925,000 -795,000 -3,634,000 5,243,000 3,602,000 294,000 -592,000 2,682,000 1,307,000 -228,000 -191,000 
          changes in operating assets and liabilities:
        		                     
          research fees and grants receivable
        		13,103,000 -39,666,000 -3,433,000 -11,391,000 -1,133,000  -19,824,000 -15,858,000 -18,576,000             
          income taxes payable
        		-4,970,000    -4,408,000  -2,756,000 -2,771,000 -3,182,000  5,801,000 35,498,000 -12,614,000 -53,675,000 -87,185,000 -17,714,000 69,965,000 16,033,000 767,000 -24,207,000 -6,123,000 
          accounts payable and accrued liabilities
        		-9,406,000 5,743,000 5,070,000 -3,947,000 -3,409,000 6,617,000 4,148,000 4,748,000 -4,878,000  975,000 2,951,000 -5,778,000 2,217,000 731,000 -2,633,000 751,000 1,713,000 3,327,000 1,554,000 -5,194,000 
          deferred revenue
        		-8,033,000 -4,511,000 -7,045,000 -3,952,000 13,313,000 5,543,000 -692,000 -4,765,000 -8,017,000 -6,738,000 -2,368,000 -965,000 -3,905,000 10,277,000 -1,115,000 -3,920,000 941,000 -427,000 4,203,000 -1,238,000 6,086,000 
          deferred grant income
        		-2,356,000 -804,000 -1,153,000 -461,000 -1,220,000 3,296,000 10,914,000 8,479,000 11,278,000 9,144,000 4,811,000        4,975,000   
          other assets
        		-1,741,000 3,070,000 628,000 6,130,000 7,320,000 4,946,000 2,481,000 2,132,000 -3,605,000 4,661,000 9,152,000 1,230,000 -6,063,000  2,913,000 3,418,000 -7,557,000  299,000   
          net cash from operating activities
        		-33,523,000 -34,743,000 -52,594,000 -32,404,000 -11,554,000 -8,000,000 -28,882,000 -29,966,000 -41,708,000 -19,611,000 -106,000 19,903,000 -44,063,000 30,912,000 -126,786,000 273,015,000 100,219,000 -16,712,000 -5,932,000 157,683,000 109,545,000 
          capital expenditures
        		-3,831,000 -9,843,000 -8,928,000 -13,365,000 -10,636,000 -15,630,000 -18,516,000 -20,110,000 -24,140,000 -14,431,000 -20,331,000 -27,201,000 -14,984,000 -12,330,000 -12,513,000 -31,322,000 -14,495,000 -9,430,000 -8,574,000 -36,804,000 -3,644,000 
          free cash flows
        		-37,354,000 -44,586,000 -61,522,000 -45,769,000 -22,190,000 -23,630,000 -47,398,000 -50,076,000 -65,848,000 -34,042,000 -20,437,000 -7,298,000 -59,047,000 18,582,000 -139,299,000 241,693,000 85,724,000 -26,142,000 -14,506,000 120,879,000 105,901,000 
          cash flows from investing activities:
        		                     
          purchases of property and equipment
        		-3,831,000 -9,843,000 -8,928,000 -13,365,000 -10,636,000 -15,630,000 -18,516,000 -20,110,000 -24,140,000 -14,431,000 -20,331,000 -27,201,000 -14,984,000 -12,330,000 -12,513,000 -31,322,000 -14,495,000 -9,430,000 -8,574,000 -36,804,000 -3,644,000 
          purchase of marketable securities
        		-166,308,000 -111,340,000 -33,162,000 -126,552,000 -164,990,000 -152,837,000 -186,242,000 -176,636,000 -249,371,000 -276,836,000 -215,783,000 -168,139,000 -360,752,000  -536,124,000 -82,532,000 -51,774,000 -29,396,000    
          proceeds from marketable securities
        		143,802,000 119,536,000 83,099,000 113,410,000 190,027,000 201,893,000 196,604,000 232,840,000 306,545,000 268,024,000 220,099,000 160,176,000 262,638,000 92,393,000 272,430,000 88,514,000 57,294,000 18,081,000    
          receipt of grant funding
        		1,361,000 13,977,000 918,000 5,430,000 1,018,000 6,558,000 9,400,000 12,582,000 7,168,000 10,288,000 7,330,000 5,000,000 2,693,000 2,334,000 6,002,000 5,502,000 2,596,000 22,814,000 5,287,000   
          long-term investments and other assets
        		-105,000 -322,000 -2,988,000 -8,182,000 -5,601,000 -2,611,000 9,588,000 8,335,000 -4,385,000 -7,892,000 0 -2,022,000 -34,735,000  -5,713,000 0 -11,657,000     
          net cash from investing activities
        		-25,081,000 75,138,000 36,488,000 -31,811,000 7,935,000 35,703,000 3,698,000 52,098,000 29,910,000 -24,323,000 -12,786,000 -34,390,000 -149,609,000 -17,063,000 -281,994,000 -27,197,000 -26,371,000 -1,149,000 -269,626,000 -45,633,000 -15,839,000 
          cash flows from financing activities:
        		                     
          proceeds from long-term liabilities and other
        		7,192,000                     
          net cash from financing activities
        		7,192,000 4,115,000 7,372,000 -3,375,000 5,970,000 4,142,000 3,145,000 2,651,000 2,831,000 3,765,000 6,630,000 419,000 -458,000 349,000 -19,000 1,173,000 -3,131,000 1,834,000 898,000 -5,075,000 -1,543,000 
          effect of exchange rate changes on cash and cash equivalents
        		-38,000 290,000 -544,000 761,000 590,000 -2,160,000 367,000 -43,000 -781,000 1,068,000 -1,063,000 797,000 -213,000 364,000 -8,552,000 -1,207,000 -204,000 -525,000 -217,000 -199,000 -484,000 
          increase in cash and cash equivalents
        		-51,450,000   -66,829,000 2,941,000       -13,271,000 -194,343,000   245,784,000 70,513,000 -16,552,000 -274,877,000 106,776,000 91,679,000 
          cash and cash equivalents and restricted cash, beginning of period
        		155,249,000 0 0 0 183,615,000 0 0 0 160,610,000 -1,000 0 1,000 414,650,000  0 0 501,142,000     
          cash and cash equivalents and restricted cash, end of period
        		103,799,000 44,800,000 -9,278,000 -66,829,000 186,556,000 29,685,000 -21,672,000 24,740,000 150,862,000 -39,102,000 -7,325,000 -13,270,000 220,307,000  -417,351,000 245,784,000 571,655,000     
          restricted cash included in other assets
        		1,736,000 -554,000 0 0 2,290,000 0 0 0 2,290,000 0 0 0 2,290,000  4,939,000       
          total cash, cash equivalents, and restricted cash shown on the balance sheet
        		102,063,000 45,354,000 -9,278,000 -66,829,000 184,266,000 29,685,000 -21,672,000 24,740,000 148,572,000 -39,102,000 -7,325,000           
          supplemental disclosure of non-cash investing and financing activities
        		                     
          property and equipment in accounts payable
        		706,000 -8,462,000 -2,276,000 1,773,000 10,960,000 -3,222,000 45,000 -2,710,000 18,654,000 677,000 1,230,000 2,800,000 8,918,000         
          right-of-use assets obtained in exchange for operating lease obligation
        		 0 6,331,000 66,426,000 3,361,000 -334,000 1,780,000 345,000 107,000 -2,387,000 641,000 821,000 2,124,000 4,455,000 47,035,000 -1,454,000 658,000 9,662,000 -2,597,000 15,385,000 14,188,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                     
          amortization and impairment of intangible assets
        		 941,000 940,000   10,464,000 33,085,000               
          fair value loss on contingent consideration and investments
        		                     
          income taxes (payable) receivable
        		                     
          distribution from equity accounted investees
        		                     
          investment in and loans to equity accounted investees
        		         -3,476,000 -3,541,000 -2,204,000 -4,469,000 -5,909,000 -4,076,000 -7,359,000 -8,335,000 -3,218,000 -6,595,000   
          proceeds from repayment of loan from joint venture partner
        		                     
          payment of liability for in-licensing agreement and other
        		 -6,409,000   -178,000 -177,000 -184,000 -183,000 -185,000             
          fair value loss on contingent consideration
        		                     
          investment in equity accounted investees
        		  -2,451,000 -2,552,000 -1,883,000  -7,136,000 -4,913,000 -5,907,000             
          proceeds from other liabilities and exercise of stock options
        		                     
          decrease in cash and cash equivalents
        		        -9,748,000 -39,101,000            
          fair value gain on contingent consideration
        		                     
          income taxes receivable
        		                     
          payment of contingent consideration and other
        		                     
          proceeds from long-term liabilities and exercise of stock options
        		   5,505,000 6,148,000                 
          fair value gain on contingent consideration and other
        		    2,213,000                 
          net earnings
        		         -47,150,000 -28,610,000 -30,528,000 -40,110,000         
          research fee and grant receivable
        		         -10,438,000            
          accrued royalties receivable
        		         0 13,000 0 9,260,000 85,205,000 -62,617,000 274,497,000 -167,914,000 -134,463,000 21,559,000 145,907,000 26,861,000 
          purchase of intangible assets
        		         0    0        
          fair value gain on contingent consideration and investments
        		                     
          deferred income tax and other
        		                     
          accrued royalties payable
        		          0 0 -16,253,000 1,524,000 -32,733,000 5,192,000 22,857,000 21,911,000 -22,925,000 3,511,000 -7,134,000 
          proceeds from long-term liabilities
        		      3,102,000 2,373,000 2,124,000             
          proceeds from exercise of stock options
        		      227,000 461,000 892,000             
          deferred tax (expense) recovery
        		                     
          change in fair value of contingent consideration and investments
        		                     
          accounts payable and other liabilities
        		                     
          acquisitions
        		                     
          payment of liability for in-licensing agreement, contingent consideration, and other
        		         -185,000            
          proceeds from long-term debt and exercise of stock options
        		            490,000         
          accounts and accrued research fees receivable
        		           -32,184,000 7,915,000 -19,040,000 3,288,000 1,788,000 -8,751,000 -3,057,000 -5,990,000 1,734,000 -30,073,000 
          payment of liability for in-licensing agreement and contingent consideration
        		           271,000 -948,000         
          proceeds (repayment) from long-term debt and exercise of stock options
        		                     
          deferred grant revenue
        		            4,525,000 2,634,000 1,224,000 724,000 4,682,000     
          total cash, cash equivalents and restricted cash shown on the balance sheet
        		            218,017,000         
          deferred tax expense
        		                 1,249,000 -4,023,000 133,000 623,000 
          operating lease liabilities
        		                 -451,000 37,000   
          other operating assets and liabilities
        		                     
          purchases of marketable securities
        		                     
          acquisitions, net of cash acquired
        		                     
          long-term investments and other
        		                     
          repayment of long-term debt and contingent consideration
        		             0 -250,000 -1,000 -72,000     
          proceeds from convertible debentures
        		                     
          net proceeds from issuance of common shares
        		                     
          proceeds from issuance of preferred shares - series a1 and a2 financing
        		                     
          cash and cash equivalents and restricted cash, beginning of year
        		                     
          cash and cash equivalents and restricted cash, end of year
        		                     
          restricted cash included within other current and other long-term assets
        		                     
          total cash, cash equivalents, and restricted cash shown on the balance sheets
        		                     
          supplemental disclosure of non-cash investing and financing activities:
        		                     
          property and equipment purchases in accounts payable
        		                     
          purchase of intangible assets in exchange for in-licensing agreement payable
        		                     
          net income
        		              26,624,000 -6,785,000 168,573,000  -21,382,000 -2,323,000 117,221,000 
          proceeds from debt and exercise of stock options
        		              231,000       
          payment of liability for in-licensing agreement
        		              0 940,000 -5,000,000 0 0   
          total cash, cash equivalents and restricted cash shown in the statement of cash flows
        		               244,897,000 570,718,000     
          property plant and equipment in accounts payable
        		               -207,000 2,353,000    423,000 
          proceeds from long-term debt and issuance of common shares pursuant to exercise of stock options
        		                1,941,000     
          restricted cash included in other long-term assets
        		                -937,000     
          repayment (issuance) of related party loans
        		                     
          repayment of long-term debt
        		                 0 0 -107,000 -1,716,000 
          proceeds from long-term debt
        		                 0 0   
          payment of contingent consideration
        		                 0 0   
          short-term borrowings
        		                     
          issuance of common shares pursuant to exercise of stock options and other
        		                     
          repayment of loan to related parties
        		                     
          long-term investments and deposits
        		                     
          issuance of common shares pursuant to exercise of stock options
        		                  898,000 1,710,000 173,000 
          proceeds from issuance of preferred shares - series a2 financing
        		                     
          cash and cash equivalents, beginning of period
        		                  0 0 594,116,000 
          cash and cash equivalents, end of period
        		                  -274,877,000 106,776,000 685,795,000 
          amortization of operating lease right-of-use-assets
        		                   693,000 661,000 
          long-term investments
        		                     
          other assets and liabilities
        		                    -1,924,000 
          investment in equity investees
        		                    -12,195,000 
          payment of deferred financing fees
        		                     
          extinguishment of long-term debt
        		                     
          accretion and other
        		                     
          unrealized foreign exchange gains and losses
        		                     
          investment tax credit receivable
        		                     
          acquisition of trianni
        		                     
          proceeds from issuance of preferred shares - series a1 financing
        		                     
          cash and cash equivalents, beginning of year
        		                     
          cash and cash equivalents, end of year